
Bayer Seeks EU Approval for Third Use of Darolutamide
Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval for its oral androgen receptor inhibitor, darolutamide, to be used in combination with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, marketed as…












